Anna Razumova

TL;DR: A large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer are compiled and identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types.

TL;DR: MSK-ACCESS as mentioned in this paper is an NGS assay for detection of very low frequency somatic alterations in 129 genes and achieved 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling.

TL;DR: The experience illustrates the importance of analyzing a matched normal sample when interpreting cfDNA results and highlights the potential of cfDNA profiling to guide treatment selection, monitor treatment response, and identify mechanisms of treatment resistance.

TL;DR: The MSK-IMPACT Heme cohort is described, a comprehensive data set of somatic alterations from paired tumor and normal DNA using a hybridization capture-based next generation sequencing platform, and the power of appropriate matching to make definitive somatic calls is demonstrated, including in patients who have undergone allogeneic stem cell transplant.

TL;DR: The MSK-ACCESS Heme (Memorial Sloan Kettering-Analysis of Circulating cfDNA to Examine Somatic Status) as discussed by the authors is a unique molecular indexing ultra-deep sequencing assay for hematologic neoplasms.